Overview of interleukin-2 inhalation therapy

Cancer Journal from Scientific American

Volumn 6, Issue SUPPL. 1, 2000, Pages

  Huland, Edith ^a   Heinzer, Hans ^a   Hartwig Huland, A ^a   Yung, Rex ^b  

^a UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^b UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

Inhalation; Interleukin 2; Pulmonary and mediastinal metastases; Quality of life; Regional therapy

Indexed keywords

RECOMBINANT INTERLEUKIN 2; INTERLEUKIN 2; ALPHA INTERFERON; ALPHA2A INTERFERON; ANTIBODY; CYTOKINE; FLUOROURACIL; ISOTRETINOIN; LIPOSOME; PENTETATE TECHNETIUM TC 99M; VINBLASTINE;

ARTICLE; BREAST CARCINOMA; CANCER THERAPY; CLINICAL TRIAL; DOSE RESPONSE; DRUG TOLERABILITY; HUMAN; KIDNEY CARCINOMA; LUNG METASTASIS; MAJOR CLINICAL STUDY; MELANOMA; META ANALYSIS; OVARY CARCINOMA; PRIORITY JOURNAL; INHALATIONAL DRUG ADMINISTRATION; KIDNEY TUMOR; NEOPLASM; QUALITY OF LIFE; REVIEW; BREAST CANCER; CANCER SURVIVAL; COUGHING; DRUG EFFICACY; DRUG SAFETY; FEVER; IMMUNE RESPONSE; LUNG ALVEOLUS CELL CARCINOMA; LUNG LAVAGE; MULTICENTER STUDY; MYALGIA; NEBULIZATION; NONHUMAN; OVARY CANCER; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL;

ADMINISTRATION, INHALATION; CARCINOMA, RENAL CELL; CLINICAL TRIALS; HUMANS; INTERLEUKIN-2; KIDNEY NEOPLASMS; MELANOMA; NEOPLASMS; QUALITY OF LIFE;

EID: 0033840128     PISSN: 10814442     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (33)

1. Huland E, Huland H, Heinzer H. Interleukin-2 by inhalation: local therapy for metastatic renal cell carcinoma. J Urol 1992; 147: 344-348.
2. Kelling S, Heinzer H, Huland E et al. In-vitro model for nebulizing interleukin-2: quantitative evaluation and biologic activity of three different preparations of nebulized interleukin-2 [abstract]. Immunobiology 1996;196:110-111.
3. Lorenz J, Wilhelm K, Kessler M et al. Phase I trial of inhaled natural interleukin 2 for treatment of pulmonary malignancy: toxicity, pharmacokinetics, and biological effects. Clin Cancer Res 1996;2:1115-1122.
4. Zissel G, Aulitzky WE, Lorenz J et al. Induction of accessory cell function of human alveolar macrophages by inhalation of human natural interleukin-2. Cancer Immunol Immunother 1996;42: 122-126.
5. Mueller-Quernheim J. Consequences of human natural interleukin-2 inhalation for the functional status of immune cells. Anticancer Res 1999;19:2009.
6. Gaede KI, Zissel G, Schwulera U et al. Spontaneous and interleukin-2-modulated cytokine release by bronchoalveolar cells in pulmonary malignancy. Eur Cytokine Netw 1997;8:395-400.
7. Huland E, Heinzer H, Falk B et al. Exclusive Inhalation von Interleukin-2 bei Patienten mit pulmonal metastaseirtem Nierenzell-karzinom: erste Ergebnisse einer multizentrischen Studie [German]. Urologe A 1994;1/94:572.
8. Abstracts of the First Symposium on Local Cytokine Therapy of Cancer: Interleukin-2, Interferon and Related Cytokines. Anticancer Res 1999;19:1995-2016.
9. Heinzer H, Mir T, Huland E et al. Subjective and objective prospective, long-term analysis of quality of life during inhaled interleukin-2 immunotherapy. J Clin Oncol 1999;17:3612-3620.
10. Huland E, Heinzer H, Vinke J et al. A comparison of two modes of administration of recombinant interleukin-2: inhalative versus systemic therapy. Eur Urol 1999;35:91.
11. Huland E, Heinzer H, Huland H. Inhaled interleukin-2 in combination with low-dose systemic interleukin-2 and interferon alpha in patients with pulmonary metastatic renal-cell carcinoma: effectiveness and toxicity of mainly local treatment. J Cancer Res Clin Oncol 1994;120:221-228.
12. Elson PJ, Witte RS, Trump DL. Prognostic factors for survival in patients with recurrent or metastatic renal cell carcinoma. Cancer Res 1988;48:7310-7313.
13. Heidenreich A, Neubauer S. Interleukin-2 inhalation therapy in pulmonary metastases of renal cell cancer - Cologne experience. Anticancer Res 1999;19:2003.
14. Varga Z, von Knobloch R. Interleukin-2 inhalation in combination with systemic alfa-interferon and vinblastine in pulmonary metastatic renal cell cancer: the Marburg experience [abstract]. Anticancer Res 1999;19:2014.
15. Nakamoto T, Kasaoka Y, Mitani S et al. Inhalation of interleukin-2 combined with subcutaneous administration of interferon for the treatment of pulmonary metastases from renal cell carcinoma. Int J Urol 1997;4:343-348.
16. Atzpodien J. Konsensusprotokoll Chemo-immuntherapie des metastasierten Nierenzellkarzinoms: subkutan Interferon-alpha 2 a, subkutan Interleukin-2 und peroral Isotretinoin mit inhalativem Interleukin-2, intravenosem 5-Fluorouracil oder peroral Capecitabine-Therapieoptimierungsvergliech [German]. Deutsche Urologisch-Internistische Multicenter-Gruppe, 1998.
17. Roigas J. Inhalation of interleukin-2 as second-line treatment: Charité experience. Anticancer Res 1999;19:2010-2011.
18. Atzpodien J. Immunotherapy in combination with inhalatory interleukin-2 therapy - first results. Anticancer Res 1999;19:1997.
19. Enk AH, Nashan D, Knop J. [Treatment of lung metastases from malignant melanoma with IL-2 inhalation therapy], Hautarzt 1997;48:894-896.
20. Enk A. Successful therapy of lung metastases in malignant melanoma by inhalative interleukin-2 therapy. Anticancer Res 1997; 17:2002.
21. Wagner U. Combination chemotherapy of pulmonary metastasized gynecological cancer with inhalative interleukin-2: results of a feasibility study. Anticancer Res 1999;19:2015.
22. Petzoldt B, Prietl G, Kohler S et al. Combination chemotherapy of pulmonary metastasized gynecological cancer with inhalative IL-2: results of a feasibility study [abstract]. J Cancer Res Clin Oncol 1998;124:137.
23. Petzoldt B, Pried G, Kupka M et al. Additive Immuntherapie bei pulmonal metastasiertem gynakologischen Karzinomen mit inhalativem Interleukin-2 [German]. Geburtshilfe Frauenheilkd 1999;59:157-162.
24. Kullmer J, Kaiser UFK, Wolf M. Interleukin-2 inhalation in advanced bronchiole-alveolar carcinoma. Anticancer Res 1999; 19: 2007.
25. Kaiser U, Pflüger K, Havemann K. Inhalation therapy with interleukin-2 in bronchio-alveolar carcinoma. Onkologie 1995;18:94.
26. Khanna C, Anderson PM, Hasz DE et al. Interleukin-2 liposome inhalation therapy is safe and effective for dogs with spontaneous pulmonary metastases. Cancer 1997;79:1409-1421.
27. Outcomes of cancer treatment for technology assessment and cancer treatment guidelines. American Society of Clinical Oncology. J Clin Oncol 1996;14:671-679.
28. Gursel M, Gregoriadis G. The immunological co-adjuvant action of liposomal interleukin-2: the role of mode of localisation of the cytokine and antigen in the vesicles. J Drug Target 1998;5:93-98.
29. Bubenik J. Local and regional immunotherapy of cancer with interleukin 2. J Cancer Res Clin Oncol 1990;116:1-7.
30. Cortesina G, De Stefani A, Galeazzi E et al. Interleukin-2 and head and neck squamous cell carcinoma: clinical and pathological studies. Pharmacol Res 1992;26[suppl 2]:50-51.
31. Den Otter W, Dobrowolski Z, Bugajski A et al. Intravesical interleukin-2 in T1 papillary bladder carcinoma: regression of marker lesion in 8 of 10 patients. J Urol 1998;159:1183-1186.
32. Huland E, Huland H. Local continuous high dose interleukin 2: a new therapeutic model for the treatment of advanced bladder carcinoma. Cancer Res 1989;49:5469-5474.
33. Pizza G, Severini G, Menniti D et al. Tumour regression after in-tralesional injection of interleukin 2 (IL-2) in bladder cancer. Preliminary report. Int J Cancer 1984;34:359-367.